[Hemostatic disorders in liver disease].
Hemorrhagic complications are common in patients with liver diseases and contribute to the morbidity and mortality associated to this condition. The liver plays a central role in the hemostatic process as here all clotting factors and their inhibitors are synthetized. Liver damage is commonly associated with variable impairment of hemostasis due to multiple causes: decreased synthesis of clotting and inhibitor factors, decreased clearance of activated factors, hyperfibrinolysis, accelerated intravascular coagulation, quantitative and qualitative platelet defects. Their clinical implications remain to be elucidated, so further studies addressing this issue are needed.
Mitrică
Dana
D
Universitatea de Medicină Si Farmacie Gr T Popa Iasi, Facultatea de Medicină, Institutul de Gastroenterologie si Hepatologie Iaşi.
Drug
V L
VL
Prelipcean
Cristina Cijevschi
CC
Stan
Mărioara
M
D020152:Antithrombin III Deficiency / Q000503:physiopathology; D001779:Blood Coagulation Factors / Q000096:biosynthesis*; D004211:Disseminated Intravascular Coagulation / Q000503:physiopathology; D005342:Fibrinolysis; D006487:Hemostasis; D020141:Hemostatic Disorders / Q000209:etiology* / Q000503:physiopathology; D015844:Heparin Cofactor II / Q000172:deficiency; D006801:Humans; D008107:Liver Diseases / Q000150:complications* / Q000503:physiopathology; D020151:Protein C Deficiency / Q000503:physiopathology; D018455:Protein S Deficiency / Q000503:physiopathology; D015842:Serine Proteinase Inhibitors / Q000172:deficiency; D013921:Thrombocytopenia / Q000209:etiology
D001779:Blood Coagulation Factors; D015842:Serine Proteinase Inhibitors; D015844:Heparin Cofactor II